Study to Understand Novel Biomarkers in Researching Dementia
Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Aug 6, 2024
Trial Information
Current as of October 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to better understand certain substances in the blood that may help diagnose Alzheimer's disease and other types of dementia. Researchers want to see how well these blood markers, specifically amyloid and tau proteins, relate to brain health and memory problems. By finding reliable blood tests, the hope is to improve early diagnosis and treatment options for people experiencing symptoms of Alzheimer’s.
To participate in this study, you need to be at least 60 years old and have some signs of memory loss or cognitive difficulties, like mild cognitive impairment or mild dementia. Most participants will have these symptoms, but anyone from the SEABIRD group can join, no matter their memory status. If you qualify, you can expect to provide blood samples and participate in various study activities. It's important to note that those with severe cognitive impairment or certain health conditions may not be eligible. This study is currently recruiting participants, so it’s an opportunity to contribute to important research that could help many people in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 60 years of age
- • 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
- • All SEABIRD participants will be invited to participate regardless of their cognitive status
- Exclusion Criteria:
- • Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
- • Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
- • Taking a disease-modifying drug for AD at time of enrollment
- • Blood transfusion in the last three months
- • Unwilling or unable to participate in all study activities
About Washington University School Of Medicine
Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Randall Bateman, MD
Principal Investigator
Washington University School of Medicine
David Carr, MD
Study Director
Washington University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported